Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$45.05 -1.2%	$46.93	$42.96 ▼ $63.33	$92.82B	0.35	9.94 million shs	28.35 million shs
CSLLY CSL	$65.38 -0.7%	$77.79	$64.68 ▼ $101.44	$63.88B	0.78	173,681 shs	202,548 shs
GSK GSK	$40.63 +0.8%	$38.90	$31.72 ▼ $42.63	$82.08B	0.53	3.61 million shs	3.69 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.12%	-2.53%	-6.63%	-3.88%	-9.43%
CSLLY CSL	-0.73%	-4.44%	-7.60%	-16.02%	-35.01%
GSK GSK	+0.83%	-0.44%	+1.43%	+6.94%	-4.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$45.05 -1.2%	$46.93	$42.96 ▼ $63.33	$92.82B	0.35	9.94 million shs	28.35 million shs
CSLLY CSL	$65.38 -0.7%	$77.79	$64.68 ▼ $101.44	$63.88B	0.78	173,681 shs	202,548 shs
GSK GSK	$40.63 +0.8%	$38.90	$31.72 ▼ $42.63	$82.08B	0.53	3.61 million shs	3.69 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.12%	-2.53%	-6.63%	-3.88%	-9.43%
CSLLY CSL	-0.73%	-4.44%	-7.60%	-16.02%	-35.01%
GSK GSK	+0.83%	-0.44%	+1.43%	+6.94%	-4.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.24	Hold	$56.38	25.14% Upside
CSLLY CSL	2.50	Moderate Buy	N/A	N/A
GSK GSK	1.86	Reduce	$37.38	-8.01% Downside

Current Analyst Ratings Breakdown

Latest BMY, GSK, and CSLLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2025	CSLLY CSL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/1/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$51.00 ➝ $47.00
7/31/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$36.00 ➝ $34.00

(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.90	$5.81 per share	7.75	$8.08 per share	5.58
CSLLY CSL	$15.56B	4.08	$4.34 per share	15.06	$22.10 per share	2.96
GSK GSK	$40.10B	2.06	$5.63 per share	7.22	$8.07 per share	5.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.48	18.17	7.40	2.33	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
CSLLY CSL	$3.00B	N/A	0.00	15.99	1.52	N/A	N/A	N/A	10/30/2025 (Estimated)
GSK GSK	$3.29B	$2.16	18.81	8.74	2.01	10.81%	49.22%	11.31%	10/29/2025 (Estimated)

Latest BMY, GSK, and CSLLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion
7/30/2025	Q2 2025	GSK GSK	$1.12	$1.23	+$0.11	$0.94	$7.92 billion	$10.64 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.50%	N/A	100.00%	17 Years
CSLLY CSL	$1.52	2.32%	N/A	N/A	N/A
GSK GSK	$1.68	4.13%	N/A	77.78%	N/A

Latest BMY, GSK, and CSLLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
9/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.36%	10/3/2025	10/3/2025	11/3/2025
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.54	1.21	1.11
CSLLY CSL	0.50	2.46	1.12
GSK GSK	1.07	0.87	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
CSLLY CSL	N/A
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CSLLY CSL	32,698	970.00 million	N/A	Not Optionable
GSK GSK	68,629	2.04 billion	1.83 billion	Optionable

BMY, GSK, and CSLLY Headlines

Recent News About These Companies

GSK PLC Sponsored ADR $GSK Stock Holdings Lifted by Miller Howard Investments Inc. NY

5 hours ago | marketbeat.com

Their Experiences Are Unique. Their Resolve Isn’t.

September 19 at 11:48 PM | theatlantic.comT

GSK Commits $30 billion to US R&D and Manufacturing

September 19 at 1:47 PM | technologynetworks.comT

GSK ups US investment with $30B spending plan

September 19 at 8:46 AM | biopharmadive.comB

Emma Walmsley’s impatient overhaul of GSK

September 19 at 8:46 AM | finance.yahoo.com

GSK Just Dropped $30 Billion on America's Biotech Future--Here's What That Buys

September 18 at 5:00 AM | finance.yahoo.com

GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years

September 17 at 1:01 PM | zacks.com

First Bank & Trust Takes $1.22 Million Position in GSK PLC Sponsored ADR $GSK

September 17 at 6:49 AM | marketbeat.com

British pharma giant GSK announces $30B investment in US

September 17 at 4:58 AM | newsbytesapp.comN

Britain's GSK Vows $30 Bn Investment In US As Trump Visits

September 17 at 4:58 AM | barrons.com

GSK plans $30bn investment for R&D in US

September 17 at 4:58 AM | pharmaceutical-technology.comP

GSK unveils $30B U.S. investment after Trump arrives in U.K. for state visit

September 17 at 4:58 AM | msn.com

GSK commits $30 billion to US research and development, factory expansion, as Trump visits UK

September 17 at 4:58 AM | msn.com

GSK commits $30bn to US drug research and manufacturing

September 17 at 3:11 AM | proactiveinvestors.co.uk

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

September 17 at 2:29 AM | cnbc.com

Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Shares

September 17 at 2:06 AM | marketbeat.com

GSK PLC Sponsored ADR (NYSE:GSK) Receives $37.38 Average Target Price from Analysts

September 17 at 2:43 AM | americanbankingnews.com

GSK Unveils $30 Billion U.S. Investment to Boost Life Sciences and Manufacturing

September 16, 2025 | devdiscourse.comD

With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years

September 16, 2025 | statnews.comS

GSK and Eli Lilly Announce Billions in U.S. Manufacturing Investments Amid Tariff Concerns

September 16, 2025 | econotimes.com

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America

September 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, GSK, and CSLLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$45.05 -0.55 (-1.21%)

Closing price 09/19/2025 03:59 PM Eastern

Extended Trading

$45.14 +0.09 (+0.20%)

As of 09/19/2025 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$65.38 -0.48 (-0.73%)

As of 09/19/2025 03:59 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$40.63 +0.33 (+0.82%)

Closing price 09/19/2025 03:59 PM Eastern

Extended Trading

$40.45 -0.18 (-0.44%)

As of 09/19/2025 07:54 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, GSK, and CSLLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, GSK, and CSLLY Earnings

Compare Dividends

Latest BMY, GSK, and CSLLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, GSK, and CSLLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, GSK, and CSLLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

CSL OTCMKTS:CSLLY

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, GSK, and CSLLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, GSK, and CSLLY Earnings

Compare Dividends

Latest BMY, GSK, and CSLLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, GSK, and CSLLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, GSK, and CSLLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

CSL OTCMKTS:CSLLY

GSK NYSE:GSK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools